


UNITED STATES OF AMERICA
BEFORE THE FEDERAL TRADE COMMISSION



In the Matter of
Hoechst Marion Roussel, Inc., et al.,
Respondents

Docket No. 9293

AVENTIS PHARMACEUTICALS INC.'S INITIAL DISCLOSURES

In accordance with § 3.31(b) of the Commission's Rule of Practice, 16 C.F.R. § 3.31(b), respondent Aventis Pharmaceuticals Inc. ("Respondent"), formerly known as Hoechst Marion Roussel, Inc. ("HMRI"), hereby provides its initial disclosures. These disclosures are based on information currently known to Respondent and are subject to supplementation to the extent additional information becomes available.

Under Commission Rule 3.31(b), parties are to provide certain disclosures with respect to information and documents "relevant to the allegation of the Commission's complaint." The Complaint fails to allege certain facts with particularity. Especially given the lack of particularity in the Complaint, Aventis' inability to address herein any aspect of, or allegation in, the Complaint in a specific fashion is not meant to indicate that Respondent in any way admits or fails to dispute any such allegation, except to the extent provided in Respondent's Answer.

Set forth below are: (1) the names of individuals likely to have discoverable information relevant to the allegations of the Complaint, to the proposed relief, or to the defenses of the Respondents; and (2) a description by category and location of documents, data compilations

and tangible things in our possession, custody or control that are relevant to the allegations of the Complaint, to the proposed relief, or to the defenses of the Respondents, excluding privileged material, trial preparation material, material; that pertains to experts, and material that is obtainable from some other source that is more convenient, less burdensome or less expensive. This information is provided to the extent that it is known.

I. INDIVIDUALS LIKELY TO HAVE DISCOVERABLE INFORMATION

The Complaint alleges that Respondent has acted in a manner violative of Section 5 of the Federal Trade Commission Act. Respondent denies those allegations.

Subject to the foregoing, Respondent identifies the following person pursuant to Commission Rule 3.31(b)(1):

Andrx Corporation
4001 S.W. 47th Avenue
Fort Lauderdale, FL 33314
(954) 584-0300

Astra-Merck Inc.
Wayne, PA

Bayer Corporation
Pharmaceutical Division
400 Morgan Lane
West Haven, CT 06516
(203) 812-2000

Kelly Blinzler
Aventis Pharmaceuticals Inc.
P. O. Box 9627
Kansas City, Mo 64134
(816) 966-5000

Biovail Corporation
2488 Dunwin Drive
Mississauga, Ontario
Canada L5L LJ9
(416) 285-6000

Bruce Brydon
Biovail Corporation
2488 Dunwin Drive
Mississauga, Ontario
Canada L5L LJ9
(416) 285-6000

Gilles Caille
Quatro Scientific, Inc.
1, Place Ville-Marie, Bureau 3900
Montreal, Quebec
Canada H3B 4M7

Kenneth Cancellara
General Counsel
Biovail Corporation
2488 Dunwin Drive
Mississauga, Ontario
Canada L5L LJ9
(416) 285-6000

Frank Ciriello
Aventis Pharmaceuticals Inc.
P. O. Box 9627
Kansas City, Mo 64134
(816) 966-5000

Mark Canton
Crystaal Corporation
2488 Dunwin Drive
Mississauga, Ontario
Canada L5L LJ9
(416) 285-6000

Gilles Cote
President
Quatro Scientific, Inc.
1, Place Ville-Marie, Bureau 3900
Montreal, Quebec
Canada H3B 4M7

Faulding Inc.
200 Elmora Avenue
Elizabeth, NJ
(908) 527-9100

Forest Pharmaceuticals Inc.
13622 Lakefront Drive
St. Louis, MO 63045
(314) 344-8870

Elliot Hahn
President
Andrx Corporation
4001 S.W. 47th Avenue
Fort Lauderdale, FL 33314
(954) 584-0300

Thomas V. Heyman, Esq.
Jones, Day, Reavis & Pogue
599 Lexington Avenue
New York, NY 10022
(212) 326-3939

Lederle Laboratories
Peral River, NY

Scott Lodin, Esq.
Andrx Corporation
Vice President & General Counsel
4001 S.W. 47th Avenue
Fort Lauderdale, FL 33314
(954) 584-0300

Eugene Melnyk
Biovail
Barbados